Is tamoxifen an option for patients with endometrial stromal sarcoma? [2] (multiple letters)

Gynecologic Oncology

Volumn 96, Issue 2, 2005, Pages 561-

  Reich, Olaf ^a   Regauer, Sigrid ^a   Cohen, Ilan ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; TAMOXIFEN;

BREAST CANCER; ENDOMETRIUM SARCOMA; HORMONAL THERAPY; HUMAN; LETTER; LUNG METASTASIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

EID: 12344279834     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.11.003     Document Type: Letter

References (5)

1. I. Cohen Endometrial pathologies associated with postmenopausal tamoxifen treatment Gynecol. Oncol. 94 2004 256 266
2. S.M. Ismail Endometrial pathology associated with prolonged tamoxifen therapy: a review Adv. Anat. Pathol. 3 1996 266 271
3. M. Martin-Loeches J. Rius R.M. Orti Uterine sarcoma associated with tamoxifen use: case report Eur. J. Gynecol. Oncol. 24 2003 202 203
4. D.K. Wysowski S.F. Honig J. Beitz Uterine sarcoma associated with tamoxifen use N. Eng. J. Med. 346 2002 1832 1833
5. G.L. Eddy M.T. Mazur Endolymphatic stromal myosis associated with tamoxifen use Gynecol. Oncol. 64 1997 262 264